Compare RGS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGS | RFL |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 61.1M |
| IPO Year | 1994 | 2017 |
| Metric | RGS | RFL |
|---|---|---|
| Price | $24.15 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 103.8K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.24 | ★ 28.28 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $210,134,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.27 | ★ N/A |
| Revenue Growth | 3.52 | ★ 43.96 |
| 52 Week Low | $15.00 | $1.12 |
| 52 Week High | $31.50 | $3.19 |
| Indicator | RGS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 41.08 |
| Support Level | $23.13 | $1.15 |
| Resistance Level | $24.95 | $1.59 |
| Average True Range (ATR) | 1.17 | 0.10 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 72.61 | 2.85 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.